Click for new scientific resources and news about Corona[COVID-19]

Use Online Translation Powered By

Click Here STRS

STRS

Paper Information
Journal:   INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR)   APRIL 2010 , Volume 4 , Number 2; Page(s) 1 To 3.
 
Paper: 

DRUG UTILIZATION REVIEW OF CONVENTIONAL AMPHOTERICIN B IN FEBRILE NEUTROPENIC PATIENTS HOSPITALIZED AT A BONE MARROW TRANSPLANT CENTER
 
 
Author(s):  HAYATSHAHI ALIREZA, JAVADI MOHAMMADREZA, TORKAMANDI HASSAN, HADJIBABAIE MOLOUK*, HANAFI SOMAYEH, GHOLAMI KHEIROLLAH, ALIMOGHADDAM KAMRAN, IRAVANI MASOUD, GHAVAMZADEH ARDESHIR
 
* CLINICAL PHARMACY DEPARTMENT, FACULTY OF PHARMACY TEHRAN UNIVERSITY OF MEDICAL SCIENCES
 
Abstract: 
Introduction: Conventional amphotericin B is one of the antifungal choices as prophylactic and empiric treatment against fungal infections in febrile neutropenic patients. However the time of initiation, dosing and monitoring of drug adverse effects must be justified to maximize the efficacy and minimize the toxicities of this antifungal agent.
Methods: We conducted a prospective observational study at Shariati teaching hospital, Hematology –Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences to evaluate the appropriateness of amphotericin B utilization for our adult bone marrow transplant (BMT) patients for a period of six months.
Results: The charts of a total of 54 patients in 3 adult BMT wards were prospectively evaluated. Most patients underwent allogienic transplantation (61.1%). The mean duration of treatment with amphotericin was 9.3 days with 50% as prophylactic and 42.6% as empiric treatments. Appropriate dose was initiated in 70.4% of patients versus 22.2% unjustified initial doses. The use of amphotericin was appropriate in 92.6% of cases versus 7.4% unjustified uses.
Conclusion: Based on the results of this study, in the majority of our BMT patients amphotericin B was utilized appropriately either as prophylactic or empiric treatment. More attention in dose adjustment seems to be necessary to minimize nephrotoxicity and other adverse effects of this agent.
 
Keyword(s): AMPHOTERICIN B, FEBRILE NEUTROPENIC, EMPIRIC AND PROPHYLACTIC TREATMENT
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

HAYATSHAHI, A., & JAVADI, M., & TORKAMANDI, H., & HADJIBABAIE, M., & HANAFI, S., & GHOLAMI, K., & ALIMOGHADDAM, K., & IRAVANI, M., & GHAVAMZADEH, A. (2010). DRUG UTILIZATION REVIEW OF CONVENTIONAL AMPHOTERICIN B IN FEBRILE NEUTROPENIC PATIENTS HOSPITALIZED AT A BONE MARROW TRANSPLANT CENTER. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), 4(2), 1-3. https://www.sid.ir/en/journal/ViewPaper.aspx?id=205236



Vancouver: Copy

HAYATSHAHI ALIREZA, JAVADI MOHAMMADREZA, TORKAMANDI HASSAN, HADJIBABAIE MOLOUK, HANAFI SOMAYEH, GHOLAMI KHEIROLLAH, ALIMOGHADDAM KAMRAN, IRAVANI MASOUD, GHAVAMZADEH ARDESHIR. DRUG UTILIZATION REVIEW OF CONVENTIONAL AMPHOTERICIN B IN FEBRILE NEUTROPENIC PATIENTS HOSPITALIZED AT A BONE MARROW TRANSPLANT CENTER. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR). 2010 [cited 2021June19];4(2):1-3. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=205236



IEEE: Copy

HAYATSHAHI, A., JAVADI, M., TORKAMANDI, H., HADJIBABAIE, M., HANAFI, S., GHOLAMI, K., ALIMOGHADDAM, K., IRAVANI, M., GHAVAMZADEH, A., 2010. DRUG UTILIZATION REVIEW OF CONVENTIONAL AMPHOTERICIN B IN FEBRILE NEUTROPENIC PATIENTS HOSPITALIZED AT A BONE MARROW TRANSPLANT CENTER. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), [online] 4(2), pp.1-3. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=205236.
 
  pdf-File
Yearly Visit 58
 
 
Latest on Blog
Enter SID Blog